黄芪防治肝纤维化的研究现状  

Research Development of Astragalus in Treating Hepatic Fibrosis

作　　者：张莎莎[1] 张旭[1] 吕文良[2] 

机构地区：[1]湖州市第一人民医院,浙江湖州313000 [2]中国中医科学院广安门医院,北京100053

出　　处：《中华中医药学刊》2013年第11期2384-2387,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家"十一五"科技重大专项传染病重大专项(2009ZX10005-017);首都医学发展基金项目(SF2007-Ⅲ-31)

摘　　要：肝纤维化为诸多慢性肝病发展至肝硬化过程中所共有的病理组织学变化,在慢性肝病的治疗中,抗纤维化的治疗是非常重要的一个方面,也是治疗中的难点、研究中的热点。能否阻断肝纤维化的形成与发展,是影响慢性肝病预后的重要环节,对阻止或延缓慢性肝病向肝硬化的转变具有重要意义。益气活血法是中医临床治疗肝纤维化的重要方法,而益气则是诸法的根本和关键。掌握补气药黄芪防治肝纤维化作用的研究现状有利于进一步研究黄芪的抗纤维化机制及指导临床应用。Hepatic fibrosis （HF）is the most important pathologic course for chronic hepatic injury developing into he- patic cirrhosis. It is meaningful for treating liver disease by inhibiting the development of hepatic fibrosis and is also the difficult and hot research issue. Reversing the development of liver fibrosis or not takes an important part in the prognosis of chronic liver disease, and it can prevent or delay its transformation. Supplementing qi to remove stasis and phlegm is an important clinical method for treating HF in traditional Chinese medicine. Supplementing qi plays an essential role in this method. Handling the research status of treating HF with astragalus is helpful for further exploring the anti - fibrotic mechanism of astragalus and directing its clinical application.

关 键 词：黄芪 肝纤维化 研究现状 综述 

分 类 号：R575.2[医药卫生—消化系统]